Table 3.
Comparison of mortality rates in Tego and control cohorts
| Control (n=6,493) |
Tego (n=10,652) |
P-value | |
|---|---|---|---|
| At-risk time, pt-years | 1,639 | 2,719 | |
| Deaths | 283 | 486 | |
| Crude mortality rate (95% CI), deaths per 100 pt-years | 17.3 (15.3–19.4) | 17.9 (16.3–19.5) | |
| Crude IRR (95% CI) | 1 (ref) | 1.04 (0.89–1.20) | 0.64 |
| Model 1: adjusted IRR (95% CI) | 1 (ref) | 1.03 (0.89–1.19) | 0.71 |
| Model 2: adjusted IRR (95% CI) | 1 (ref) | 1.02 (0.88–1.19) | 0.74 |
Notes: Model 1 adjusted for age, race, vintage and etiology in end-stage renal disease; model 2 adjusted for all variables (age, sex, race, vintage, primary cause of ESRD, diabetes, heart failure, ischemic disease, cerebrovascular disease, cardiac dysrythmia, COPD, liver disease, malignancy, and Charlson comorbidity index). Tego needlefree connector is manufactured by ICU Medical, Inc., San Clemente, CA, USA.
Abbreviations: CI, confidence interval; IRR, incidence-rate ratio; pt, patient; ref, reference.